Physician profile
Jennifer A Wright
NPI 1679179485
$5,086.17
in general payments reported to CMS, 2019-2025
38 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $170 · 2023: $1,563 · 2024: $1,438 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,672 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,671.78 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.27 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $442.08 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $323.44 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $318.34 | 2024-2025 | Rezdiffra |
| Ardelyx, INC. | $288.57 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $252.06 | 2023-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.48 | 2023-2025 | Xifaxan |
| Pfizer INC. | $201.47 | 2021-2025 | |
| Gilead Sciences, INC. | $174.04 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $163.07 | 2023-2025 | Ocaliva |
| Janssen Biotech, INC. | $154.34 | 2023-2025 | Tremfya, Stelara, Remicade |
| Edwards Lifesciences Corporation | $144.25 | 2023 | Hemosphere |
| Vivus LLC | $143.57 | 2024-2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $120.88 | 2023 | |
| Celgene Corporation | $108.22 | 2023-2024 | Zeposia |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.